author-photo

Joseph R. Mace

Sarah Cannon Research Institute

14

Papers

141

Citations

Citation Trend

Filter By

Papers (14) Sort By

Journal Conference Others

Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA Trial

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Meaningful Changes in Patient-Reported Outcomes in Relation to Best Clinical Response and Disease Progression: Post Hoc Analyses from MAIA

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose-expansion cohort.

2021 American Journal of Hematology
Show All
- Source
- Cite
- Save
Citations (2)
MM-155: Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM)

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (1)
OAB-001: Overall survival and progression-free survival by treatment duration with Daratumumab + Lenalidomide/Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.

2021 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Overall survival with daratumumab, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma (MAIA): a randomised, open-label, phase 3 trial

2021
Show All
- Source
- Cite
- Save
Citations (0)
Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B‐Cell Lymphoma Who Are Poor Candidates for R‐CHOP Chemotherapy

2019 Oncologist
Show All
- Source
- Cite
- Save
Citations (5)
Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)

2018 Blood
Show All
- Source
- Cite
- Save
Citations (40)
A Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Final Analysis of Second Dose Expansion

2016 Blood
Show All
- Source
- Cite
- Save
Citations (5)